Alicia Duyvejonck
Nurse Practitioner · Springfield, ORNPI 1366858334
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $237,699 of the $298,598 with a category attached, or 79.6%. 37 manufacturers reported payments, led by AbbVie at 44.2% of the total. Reporting peaked in 2022 at $99,922 and has fallen 78.6% since, to $21,430 in 2025. Among nurse practitioner clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,056 payments — averaging $282.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$132K
- Lilly USA, LLC$61K
- Lundbeck LLC$45K
- Biohaven Pharmaceutical Holding Company Ltd.$26K
- Biohaven Pharmaceuticals, Inc.$14K
- Impel Pharmaceuticals Inc.$10K
- plus $11K from 31 others
What the payments were for
- Consulting fees$19,4867%
- Speaking & faculty fees$237,69980%
- Grants$880%
- Travel & lodging$19,5807%
- Food & beverage$21,5117%
- Education$2340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 358 | $131,958 |
| Lilly USA, LLC | 136 | $60,873 |
| Lundbeck LLC | 153 | $45,221 |
| Biohaven Pharmaceutical Holding Company Ltd. | 94 | $25,875 |
| Biohaven Pharmaceuticals, Inc. | 82 | $13,662 |
| Impel Pharmaceuticals Inc. | 30 | $10,046 |
| H. Lundbeck A S | 8 | $4,456 |
| Tonix Medicines, Inc. | 5 | $1,082 |
| Jazz Pharmaceuticals Inc. | 18 | $919 |
| Amgen | 23 | $591 |
| Idorsia Pharmaceuticals US Inc | 21 | $556 |
| Biogen | 8 | $427 |
| Pfizer | 21 | $388 |
| Teva Pharmaceuticals USA, Inc. | 22 | $312 |
| Upsher-smith Laboratories LLC | 8 | $267 |
| Axsome Therapeutics, Inc. | 8 | $256 |
| Harmony Biosciences LLC | 13 | $228 |
| Otsuka America Pharmaceutical, Inc. | 2 | $220 |
| EMD Serono, Inc. | 2 | $167 |
| Eisai Inc. | 3 | $146 |
| Genentech USA, Inc. | 2 | $131 |
| Johnson & Johnson | 3 | $129 |
| Corcept Therapeutics | 1 | $126 |
| Novartis | 6 | $92 |
| Merck | 4 | $80 |
| Scilex Pharmaceuticals Inc. | 4 | $71 |
| Impel Pharmaceuticals LLC | 6 | $45 |
| Currax Pharmaceuticals LLC | 3 | $43 |
| Supernus Pharmaceuticals, Inc. | 3 | $40 |
| TG Therapeutics, Inc. | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $32 |
| Bayer | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| AstraZeneca | 1 | $20 |
| UCB, Inc. | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$298,598 in reported general payments places this provider in the 95th percentile of 997 nurse practitioner providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 261 | $410,147 |
| Nurtec OdtRimegepant Sulfate | 116 | $144,306 |
| QuliptaAtogepant | 128 | $130,624 |
| Aimovig AutoinjectorErenumab-Aooe | 156 | $124,098 |
| ReyvowLasmiditan Succinate | 117 | $102,499 |
| WakixPitolisant Hcl | 12 | $91,459 |
| Emgality PenGalcanezumab-Gnlm | 107 | $81,220 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 36 | $34,594 |
| Ajovy SyringeFremanezumab-Vfrm | 23 | $17,351 |
| Topiramate ErTopiramate | 21 | $16,460 |
| AptiomEslicarbazepine Acetate | 12 | $15,335 |
| BelsomraSuvorexant | 32 | $14,334 |
| Eletriptan HbrEletriptan Hydrobromide | 42 | $8,748 |
| Pregabalin | 143 | $6,189 |
| Amitriptyline Hcl | 122 | $2,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $131,958 | $540,771389 claims |
| PfizerNurtec Odt | $388 | $144,306116 claims |
| Lilly USA, LLCReyvow | $60,873 | $102,499117 claims |
| Harmony Biosciences LLCWakix | $228 | $91,45912 claims |
| MerckBelsomra | $80 | $14,33432 claims |
| Upsher-smith Laboratories LLCTopiramate | $267 | $1,15873 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 997 nurse practitioner providers in Oregon.
Other nurse practitioner in Springfield
- Desiree CihelkaSpringfield$8K
- Mallory CrownoverSpringfield$6K
- Jennifer EricsonSpringfield$6K
- Parker-Leigh EvansSpringfield$1K
- Zachariah ManningSpringfield$884
- April FullerSpringfield$879
- Summer HarnessLake Oswego$113K
- Alana WilsonPortland$58K
- Jennifer MurdochPortland$15K
- Berhane MebratuPortland$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.